Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas

Prakash Rath, Huidong Shi, Joel A. Maruniak, N. Scott Litofsky, Bernard L. Maria, Mark D. Kirk

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

The prognosis of patients diagnosed with malignant gliomas including glioblastoma multiforme (GBM) is poor and there is an urgent need to develop and translate novel therapies into the clinic. Neural stem cells display remarkable tropism toward GBMs and thus may provide a platform to deliver oncolytic agents to improve survival. First we provide a brief review of clinical trials that have used intra-tumoral herpes simplex virus thymidine kinase (HSV/tk) gene therapy to treat brain tumors. Then, we review recent evidence that neural stem cells can be used to deliver HSV/tk to GBMs in animal models. While previous clinical trials used viruses or non-migratory vector-producing cells to deliver HSV/tk, the latter approaches were not effective in humans, primarily because of satellite tumor cells that escaped surgical resection and survived due to low efficiency delivery of HSV/tk. To enhance delivery of HSV/tk to kill gliomas cells, recent animal studies have focused on the ability of neural stem cells, transduced with HSV/tk, to migrate efficiently and selectively to regions occupied by GBM cells. This approach holds the promise of targeting GBM cells that have infiltrated the brain well beyond the original site of the tumor epicenter.

Original languageEnglish (US)
Pages (from-to)44-49
Number of pages6
JournalCurrent Stem Cell Research and Therapy
Volume4
Issue number1
DOIs
StatePublished - Oct 12 2009

Fingerprint

Thymidine Kinase
Simplexvirus
Glioma
Genetic Therapy
Stem Cells
Neural Stem Cells
Glioblastoma
Clinical Trials
Tropism
Brain Neoplasms
Neoplasms
Animal Models
Viruses
Survival
Brain

Keywords

  • Bystander effect
  • Glioblastoma multiforme
  • Herpes Simplex Virus/thymidine kinase
  • Neural stem cells
  • Tropism

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. / Rath, Prakash; Shi, Huidong; Maruniak, Joel A.; Litofsky, N. Scott; Maria, Bernard L.; Kirk, Mark D.

In: Current Stem Cell Research and Therapy, Vol. 4, No. 1, 12.10.2009, p. 44-49.

Research output: Contribution to journalReview article

Rath, Prakash ; Shi, Huidong ; Maruniak, Joel A. ; Litofsky, N. Scott ; Maria, Bernard L. ; Kirk, Mark D. / Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. In: Current Stem Cell Research and Therapy. 2009 ; Vol. 4, No. 1. pp. 44-49.
@article{96e46ce3eaf14aa4af47fc5d97ea3f91,
title = "Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas",
abstract = "The prognosis of patients diagnosed with malignant gliomas including glioblastoma multiforme (GBM) is poor and there is an urgent need to develop and translate novel therapies into the clinic. Neural stem cells display remarkable tropism toward GBMs and thus may provide a platform to deliver oncolytic agents to improve survival. First we provide a brief review of clinical trials that have used intra-tumoral herpes simplex virus thymidine kinase (HSV/tk) gene therapy to treat brain tumors. Then, we review recent evidence that neural stem cells can be used to deliver HSV/tk to GBMs in animal models. While previous clinical trials used viruses or non-migratory vector-producing cells to deliver HSV/tk, the latter approaches were not effective in humans, primarily because of satellite tumor cells that escaped surgical resection and survived due to low efficiency delivery of HSV/tk. To enhance delivery of HSV/tk to kill gliomas cells, recent animal studies have focused on the ability of neural stem cells, transduced with HSV/tk, to migrate efficiently and selectively to regions occupied by GBM cells. This approach holds the promise of targeting GBM cells that have infiltrated the brain well beyond the original site of the tumor epicenter.",
keywords = "Bystander effect, Glioblastoma multiforme, Herpes Simplex Virus/thymidine kinase, Neural stem cells, Tropism",
author = "Prakash Rath and Huidong Shi and Maruniak, {Joel A.} and Litofsky, {N. Scott} and Maria, {Bernard L.} and Kirk, {Mark D.}",
year = "2009",
month = "10",
day = "12",
doi = "10.2174/157488809787169138",
language = "English (US)",
volume = "4",
pages = "44--49",
journal = "Current Stem Cell Research and Therapy",
issn = "1574-888X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas

AU - Rath, Prakash

AU - Shi, Huidong

AU - Maruniak, Joel A.

AU - Litofsky, N. Scott

AU - Maria, Bernard L.

AU - Kirk, Mark D.

PY - 2009/10/12

Y1 - 2009/10/12

N2 - The prognosis of patients diagnosed with malignant gliomas including glioblastoma multiforme (GBM) is poor and there is an urgent need to develop and translate novel therapies into the clinic. Neural stem cells display remarkable tropism toward GBMs and thus may provide a platform to deliver oncolytic agents to improve survival. First we provide a brief review of clinical trials that have used intra-tumoral herpes simplex virus thymidine kinase (HSV/tk) gene therapy to treat brain tumors. Then, we review recent evidence that neural stem cells can be used to deliver HSV/tk to GBMs in animal models. While previous clinical trials used viruses or non-migratory vector-producing cells to deliver HSV/tk, the latter approaches were not effective in humans, primarily because of satellite tumor cells that escaped surgical resection and survived due to low efficiency delivery of HSV/tk. To enhance delivery of HSV/tk to kill gliomas cells, recent animal studies have focused on the ability of neural stem cells, transduced with HSV/tk, to migrate efficiently and selectively to regions occupied by GBM cells. This approach holds the promise of targeting GBM cells that have infiltrated the brain well beyond the original site of the tumor epicenter.

AB - The prognosis of patients diagnosed with malignant gliomas including glioblastoma multiforme (GBM) is poor and there is an urgent need to develop and translate novel therapies into the clinic. Neural stem cells display remarkable tropism toward GBMs and thus may provide a platform to deliver oncolytic agents to improve survival. First we provide a brief review of clinical trials that have used intra-tumoral herpes simplex virus thymidine kinase (HSV/tk) gene therapy to treat brain tumors. Then, we review recent evidence that neural stem cells can be used to deliver HSV/tk to GBMs in animal models. While previous clinical trials used viruses or non-migratory vector-producing cells to deliver HSV/tk, the latter approaches were not effective in humans, primarily because of satellite tumor cells that escaped surgical resection and survived due to low efficiency delivery of HSV/tk. To enhance delivery of HSV/tk to kill gliomas cells, recent animal studies have focused on the ability of neural stem cells, transduced with HSV/tk, to migrate efficiently and selectively to regions occupied by GBM cells. This approach holds the promise of targeting GBM cells that have infiltrated the brain well beyond the original site of the tumor epicenter.

KW - Bystander effect

KW - Glioblastoma multiforme

KW - Herpes Simplex Virus/thymidine kinase

KW - Neural stem cells

KW - Tropism

UR - http://www.scopus.com/inward/record.url?scp=67650127424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650127424&partnerID=8YFLogxK

U2 - 10.2174/157488809787169138

DO - 10.2174/157488809787169138

M3 - Review article

C2 - 19149629

AN - SCOPUS:67650127424

VL - 4

SP - 44

EP - 49

JO - Current Stem Cell Research and Therapy

JF - Current Stem Cell Research and Therapy

SN - 1574-888X

IS - 1

ER -